Italia markets close in 3 hours 46 minutes

CRVS Jul 2024 1.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,05000,0000 (0,00%)
In data: 04:02PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0500
Aperto0,0500
Denaro0,0500
Domanda0,1500
Prezzo d'esercizio1,00
Scadenza2024-07-19
Min-Max giorno0,0500 - 0,0500
Contratto - Min-MaxN/D
Volume1
Open Interest40
  • GlobeNewswire

    Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

    Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024 Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m. PT BURLINGAME, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, confirmed today that it completed an End-of-Phase/Pre-Phase 3 meeting with FDA on its plans to initiate a Phase 3 registrational clinical trial of soquelitinib (formerly CPI-818),

  • GlobeNewswire

    Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

    Interim Phase 1/1b clinical results with soquelitinib and published clinical studies on mechanism of action continue to support potential of ITK inhibition as novel immunotherapy for hematologic and solid tumors Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for

  • GlobeNewswire

    Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

    Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-63